Marker Therapeutics Temettü
Temettü kriter kontrolleri 0/6
Marker Therapeutics does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-1.8%
Geri Alım Getirisi
Toplam Hissedar Getirisi | -1.8% |
Gelecekteki Temettü Verimi | n/a |
Temettü Büyümesi | n/a |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Marker shares rise as it completes construction of its cGMP manufacturing facility
Jan 13FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy
Jan 05Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29Marker Therapeutics EPS misses by $0.02
Nov 09Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if MRKR's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if MRKR's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Marker Therapeutics Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (MRKR) | n/a |
Pazarın Alt %25'i (US) | 1.5% |
Pazarın En İyi %25'i (US) | 4.5% |
Sektör Ortalaması (Biotechs) | 2.2% |
Analist tahmini (MRKR) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate MRKR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate MRKR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate MRKR's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as MRKR has not reported any payouts.